OncoZenge AB (publ) (OM:ONCOZ) Explores Strategic Options for Bupizenge? in China. To Explore Strategic Options for Introduction of Bupizenge in China.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.895 SEK | +0.13% | -5.23% | +26.05% |
Apr. 08 | Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board | CI |
Apr. 04 | OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.05% | 4.16M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ONCOZ Stock
- News OncoZenge AB
- Oncozenge Explores Strategic Options for Bupizeng in China